How to Get Leqvio (Inclisiran) in California

What Leqvio Is and Why California Patients Need It

Leqvio is a small-interfering RNA (siRNA) therapy that silences the gene encoding PCSK9 in hepatocytes, reducing LDL-cholesterol by roughly 50% on top of existing statin therapy. The FDA approved inclisiran in December 2021 for adults with HeFH or established ASCVD who require additional LDL lowering beyond maximally tolerated statin and ezetimibe therapy [1]. Because the drug is administered by a healthcare professional twice yearly after two loading doses, it sidesteps the adherence problems that affect daily pills.

California has one of the largest pools of patients with uncontrolled LDL in the United States. The CDC estimates that approximately 71 million U.S. adults have high LDL cholesterol, and fewer than half receive treatment [2]. In California, ASCVD is the leading cause of death in adults over 45, according to the California Department of Public Health. Patients whose LDL remains above 70 mg/dL despite statin therapy are precisely the population the ORION clinical program targeted.

The ORION-10 trial (N=1,561, patients with ASCVD) and ORION-11 trial (N=1,617, patients with ASCVD or ASCVD risk equivalents including HeFH) published in the New England Journal of Medicine in 2020 showed inclisiran reduced LDL by 52.3% from baseline at day 510 in ORION-10 (P<0.001 vs. placebo) and by 49.9% in ORION-11 (P<0.001 vs. placebo) [3]. Injection-site reactions occurred in 2.6% of treated patients versus 0.9% of placebo patients, and no excess of liver or kidney adverse events appeared [3].

The American College of Cardiology and American Heart Association 2022 cholesterol guidelines recommend adding a PCSK9 inhibitor for very-high-risk ASCVD patients whose LDL remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [4]. Inclisiran meets that threshold. California clinicians applying that recommendation must manage a specific access pathway that differs from most other states, particularly around specialty pharmacy distribution.

Who Can Prescribe Leqvio in California

Any licensed California prescriber with independent prescribing authority can write an inclisiran order. That includes physicians (MD or DO), nurse practitioners (NP) holding a furnishing license, and physician assistants (PA) with a supervising physician agreement or, for NPs, under California's 2023 independent practice law [5]. Pharmacists holding a collaborative practice agreement in California cannot independently initiate inclisiran because the drug is administered in a clinical setting and billed as a medical benefit rather than a pharmacy benefit in most plans.

Cardiologists and endocrinologists manage most inclisiran prescriptions today. Lipid specialists certified by the National Lipid Association also prescribe the drug regularly. Primary care physicians can prescribe, but payers often require that prior authorization documentation come from, or be supported by, a specialist note. California's telehealth statute (Business and Professions Code Section 2290.5) explicitly permits prescribing after a synchronous audio-video visit when a prior in-person exam is not clinically required [5].

HealthRX clinicians reviewing inclisiran candidates look for three chart elements before drafting a prescription: a confirmed ASCVD diagnosis or a genetic or clinical HeFH diagnosis using the Dutch Lipid Clinic Network score, documentation that the patient has been on maximally tolerated statin therapy for at least 4 weeks, and a recent fasting LDL measurement at or above 70 mg/dL (for ASCVD) or at or above 100 mg/dL (for HeFH without ASCVD) per ACC/AHA thresholds [4].

Required Labs Before Your First Inclisiran Dose

Labs are straightforward. Three tests need to be on file within 90 days of the planned first injection: a fasting lipid panel, a comprehensive metabolic panel (CMP) to assess hepatic and renal function, and a thyroid-stimulating hormone (TSH) level if secondary dyslipidemia is suspected. No pregnancy test is required by the FDA label, but California telehealth providers typically order one for women of reproductive age given limited pregnancy safety data [6].

The FDA label for inclisiran does not require ALT monitoring during therapy, though baseline liver function should be within three times the upper limit of normal before initiating treatment [1]. Patients with severe renal impairment (eGFR <30 mL/min/1.73m2) were included in the ORION-7 trial (N=16), which showed comparable LDL reduction with no dose adjustment required, so renal insufficiency alone does not exclude a patient [7].

A repeat LDL at day 90 (just before the second dose) and again at 6 months is standard monitoring. The ACC/AHA 2022 guidelines recommend targeting an LDL below 70 mg/dL in very-high-risk ASCVD and below 55 mg/dL for patients with recurrent ASCVD events [4]. If LDL response is below 30% at 6 months, adherence to background statin therapy should be reassessed before attributing the poor response to inclisiran itself.

How to Get a Leqvio Prescription Through Telehealth in California

California telehealth prescribing of inclisiran follows a defined sequence. The visit must be synchronous audio-video, lasting approximately 20-30 minutes. The clinician reviews the lipid history, confirms current statin and ezetimibe use, and checks for contraindications (known hypersensitivity to inclisiran or any excipient). A physical examination finding, such as auscultation of the heart, is not required to complete the visit under California's telehealth standard of care [5].

After the visit, the prescriber submits a prior authorization (PA) request to the patient's insurer. Most California commercial insurers and Medi-Cal require PA for inclisiran. The PA packet typically contains the diagnosis code (E78.01 for HeFH, I25.10 for coronary artery disease), LDL documentation, statin therapy records, and in some cases a specialist attestation. Processing takes 3-15 business days for commercial plans and up to 30 days for Medi-Cal managed care plans.

Once PA is approved, the specialty pharmacy dispenses the drug and ships it cold-chain to the patient's physician office, an infusion center, or a clinical partner site. Inclisiran is never self-administered at home. The first injection is given at a clinical site, as is every subsequent dose. This is a meaningful operational difference from PCSK9 monoclonal antibodies such as evolocumab (Repatha) and alirocumab (Praluent), which patients self-inject at home every 2-4 weeks [8].

The HealthRX California Inclisiran Access Framework breaks the process into four stages:

1. Eligibility screen (Day 0-2). Telehealth video visit confirms ASCVD or HeFH diagnosis, reviews statin record, and orders baseline labs if not on file.
2. PA submission (Day 2-5). Clinician submits PA with ICD-10 codes, LDL value, and statin attestation.
3. Pharmacy coordination (Day 5-20). Approved PA triggers specialty pharmacy to ship drug to the injection site.
4. First injection (Day 14-42). Patient visits an in-network clinical site for the 284 mg subcutaneous injection in the abdomen or upper arm.

This four-stage path takes 2-6 weeks end-to-end for most California commercial-plan patients. Medi-Cal patients may wait an additional 1-2 weeks for managed care PA processing.

Prior Authorization Requirements in California

Prior authorization is the single biggest access hurdle in California. Most plans model their criteria on the Institute for Clinical and Economic Review (ICER) framework and the ACC/AHA 2022 guideline thresholds [4]. Required documentation almost always includes the items below.

A clinical diagnosis of HeFH (Dutch Lipid Clinic Network score of 6 or above, or a confirmed pathogenic LDL receptor variant) or established ASCVD (myocardial infarction, stroke, peripheral artery disease, or coronary revascularization). A fasting LDL at or above 70 mg/dL despite high-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) for at least 3 months. Documentation that ezetimibe 10 mg daily has been tried for at least 90 days, unless contraindicated or not tolerated. Some plans also request a 90-day trial of a PCSK9 monoclonal antibody before approving inclisiran, though this step-edit is being challenged by the National Lipid Association as clinically unnecessary given the equivalent LDL-reduction data [9].

California's Department of Managed Health Care (DMHC) gives enrollees the right to an expedited PA decision within 72 hours when a treating physician attests that the standard 30-day timeline would seriously jeopardize the enrollee's life or health. Cardiologists treating very-high-risk patients with recurrent MI should invoke this expedited pathway.

Novartis operates an independent patient assistance program called the Leqvio Support Center (1-833-LEQVIO1) that assigns a reimbursement specialist to each California patient. Separately, Novartis's Kisqali & Leqvio copay program caps out-of-pocket cost at $0 per injection for commercially insured patients whose plan requires a copay [10].

California 503A Pharmacies and Inclisiran Compounding

Inclisiran is not available as a compounded product from California 503A pharmacies. The drug's siRNA chemistry requires sterile manufacturing conditions and proprietary GalNAc-conjugation technology that no independent compounding pharmacy currently replicates at scale. The FDA's current bulk drug substance list does not include inclisiran as an approved 503A compoundable agent [11].

California's Board of Pharmacy regulates 503A pharmacies under the California Pharmacy Law (Business and Professions Code Section 4000 et seq.) and federal FDCA Section 503A. A 503A pharmacy may compound inclisiran only if the FDA lists it on the 503A bulks list, which has not occurred as of January 2025. Any California pharmacy advertising compounded inclisiran should be reported to the California State Board of Pharmacy.

This is a meaningful distinction for patients comparing inclisiran with compounded semaglutide or compounded tirzepatide, where 503A compounding is actively debated. For inclisiran, there is no legal compounding pathway at this time, and the branded Leqvio product obtained through a specialty pharmacy remains the only available form [11].

Transferring an Out-of-State Leqvio Prescription to California

Patients moving to California with an active inclisiran prescription in another state cannot directly transfer the prescription to a California prescriber in the way a pharmacy-dispensed oral drug transfers. Because inclisiran is a specialty drug billed as a medical benefit and administered at a clinical site, the patient's new California provider must issue a new prescription and restart the PA process with the California-based insurer or Medi-Cal plan.

The clinical record from the out-of-state provider, including LDL history, statin documentation, and previous PA approvals, can accelerate the new PA significantly. Most California commercial plans accept prior PA approval from another state as supporting documentation, and some waive the ezetimibe step-edit if the out-of-state record shows the drug was already tried [4].

Timing the transition around the injection schedule matters. If a patient is due for a 6-month dose and is mid-move, a 4-6 week delay is unlikely to materially reduce LDL benefit given inclisiran's pharmacokinetic profile. The ORION-3 open-label extension (N=290) showed that LDL control was maintained even when a dose was delayed by up to 3 months, without rebound to pre-treatment levels [12].

Insurance Coverage: Medi-Cal, Covered California, and Medicare

Medi-Cal. Inclisiran is on the Medi-Cal fee-for-service formulary with prior authorization for HeFH (E78.01) and ASCVD (I25.x). Medi-Cal managed care plans (such as LA Care or Health Net Community Solutions) each maintain separate formularies. The PA criteria mirror the ACC/AHA 2022 guideline thresholds [4]. Patients enrolled in dual Medicare-Medi-Cal plans (Cal MediConnect) may face a Medicare Part B adjudication first, since inclisiran is typically a medical benefit billed under Part B when administered in a physician office [13].

Covered California. All Covered California Qualified Health Plans must cover FDA-approved ASCVD therapies. Inclisiran falls under the specialty tier in most silver and gold plans, with a PA requirement. The 2023 Inflation Reduction Act caps Medicare Part D out-of-pocket spending at $2,000 annually, but inclisiran under Part B is subject to the standard 20% coinsurance after the deductible, which can be offset by supplemental (Medigap) coverage [13].

Medicare Part B. When a physician administers inclisiran in a clinical office, it is billed under Part B as a physician-administered drug. The reimbursement rate is set quarterly by CMS at average sales price (ASP) plus 6%. Patients without supplemental coverage may owe approximately 20% of ASP, which at current pricing is roughly $800-900 per injection before the Novartis copay card [10].

What to Expect at Your Inclisiran Injection Appointment

The injection itself takes under 5 minutes. A 284 mg dose of inclisiran sodium is drawn from a single-dose prefilled syringe and injected subcutaneously into the abdomen, upper arm, or thigh. The injection must be given by a licensed healthcare professional; it cannot be self-administered. The ACC/AHA 2022 guidelines allow nurse practitioners and physician assistants to administer the injection under an approved office protocol [4].

After injection, the patient is typically observed for 5-10 minutes for hypersensitivity reactions, though anaphylaxis has not been reported in clinical trials. The most common adverse event remains injection-site reactions, occurring in 2.6% of participants in the ORION-10 and ORION-11 trials versus 0.9% in the placebo arms [3]. No dose adjustment is required for age, sex, race, body weight, mild-to-moderate renal impairment, or mild hepatic impairment [1].

The next injection is scheduled exactly 90 days after day 1 for the loading phase, then every 6 months thereafter. Missing the 6-month window by up to 3 months does not require restarting the loading sequence, according to the FDA label [1]. A reminder system, often managed by the specialty pharmacy or the Leqvio Support Center, helps California patients track their injection dates.

LDL should be remeasured at day 90 (immediately before dose 2) and at month 6. If LDL is above target at month 6 despite inclisiran, the clinician should confirm statin adherence, rule out secondary causes of hyperlipidemia (hypothyroidism, nephrotic syndrome, obstructive liver disease), and consider whether bempedoic acid (Nexletol) adds further LDL reduction [14].

Safety Profile and Drug Interactions

The ORION-9 trial (N=482, HeFH patients) confirmed inclisiran's safety in a genetically defined high-risk group, showing a 39.7% placebo-adjusted LDL reduction at day 510 with no increase in serious adverse events versus placebo (P<0.001) [15]. No clinically meaningful drug-drug interactions have been identified. Inclisiran is not a substrate for cytochrome P450 enzymes and does not affect the pharmacokinetics of statins, ezetimibe, warfarin, or direct oral anticoagulants [1].

Women who are pregnant or breastfeeding should not use inclisiran. The FDA label carries a warning that LDL reduction in early pregnancy may harm fetal development because cholesterol is required for fetal steroid synthesis [1]. California prescribers must confirm negative pregnancy status and counsel patients on contraception before initiating the drug.

No data exist on inclisiran use in patients under 18. The FDA has not approved inclisiran for pediatric HeFH; evolocumab (Repatha) holds a pediatric indication for HoFH in patients aged 13 and older [8].